Compare NX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | PHAR |
|---|---|---|
| Founded | 1927 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.6M | 885.7M |
| IPO Year | 2008 | 2020 |
| Metric | NX | PHAR |
|---|---|---|
| Price | $16.94 | $14.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $28.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 446.3K | 4.4K |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $4.26 | $10.04 |
| Revenue Next Year | $1.77 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $9.54 |
| 52 Week High | $22.90 | $21.34 |
| Indicator | NX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 62.60 |
| Support Level | $16.90 | $12.98 |
| Resistance Level | $18.07 | $14.81 |
| Average True Range (ATR) | 0.89 | 0.39 |
| MACD | 0.09 | 0.21 |
| Stochastic Oscillator | 33.69 | 100.00 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.